TransMedics (TMDX) Receivables (2018 - 2026)

TransMedics' Receivables history runs 9 years deep, the most recent figure standing at $90.7 million for Q1 2026.

• On a quarterly basis, Receivables fell 36.12% year-over-year to $90.7 million in Q1 2026; TTM through Mar 2026 was $90.7 million, a 36.12% decrease from a year earlier, with the FY2025 full-year figure at $84.3 million, down 13.75% from the prior year.
• Receivables climbed to $90.7 million in Q1 2026 per TMDX's latest filing, from $84.3 million in the prior quarter.
• Across five years, Receivables topped out at $142.0 million in Q1 2025 and bottomed at $11.7 million in Q1 2022.
• The 5-year median for Receivables is $80.7 million (2025), against an average of $67.0 million.
• Across the five-year window, Receivables surged 430.96% in 2022 and slumped 36.12% in 2026, its largest moves.
• Year by year, Receivables stood at $27.6 million in 2022, then jumped by 130.26% to $63.6 million in 2023, then soared by 53.71% to $97.7 million in 2024, then dropped by 13.75% to $84.3 million in 2025, then advanced by 7.65% to $90.7 million in 2026.
• Per Business Quant, the three latest TMDX Receivables figures stand at $90.7 million (Q1 2026), $84.3 million (Q4 2025), and $80.7 million (Q3 2025).